StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report issued on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX opened at $0.70 on Friday. Eagle Pharmaceuticals has a one year low of $0.10 and a one year high of $14.78. The stock has a market capitalization of $9.09 million, a P/E ratio of 0.59 and a beta of 0.51. The business’s 50-day simple moving average is $3.29 and its 200-day simple moving average is $4.16.

Institutional Investors Weigh In On Eagle Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC increased its holdings in shares of Eagle Pharmaceuticals by 75.7% in the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 2,861 shares during the period. Creative Planning acquired a new position in Eagle Pharmaceuticals in the third quarter valued at $59,000. Mackenzie Financial Corp acquired a new position in Eagle Pharmaceuticals in the second quarter valued at $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $65,000. Finally, Fidelis Capital Partners LLC acquired a new stake in shares of Eagle Pharmaceuticals during the second quarter worth about $71,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.